Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP02799587A	2006-09-21	STRAWMAN LIMITED	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9402805	NOVARTIS	Method of treating middle ear infections	Sep, 2022 (1 year, 20 days ago)
US9149486	NOVARTIS	Method of treating middle ear infections	Sep, 2022 (1 year, 20 days ago)
US9345714	NOVARTIS	Method of treating middle ear infections	Sep, 2022 (1 year, 20 days ago)
US8846650	NOVARTIS	Method of treating middle ear infections	Jun, 2025 (1 year, 8 months from now)

Ciprodex is owned by Novartis.

Ciprodex contains Ciprofloxacin; Dexamethasone.

Ciprodex has a total of 4 drug patents out of which 3 drug patents have expired.

Expired drug patents of Ciprodex are:

Ciprodex was authorised for market use on 18 July, 2003.

Ciprodex is available in suspension/drops;otic dosage forms.

Ciprodex can be used as treatment of acute otitis media; treatment of acute otitis externa, treatment of acute otitis media.

The generics of Ciprodex are possible to be released after 04 June, 2025.

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media; Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.3%/0.1%	31 Jul, 2012	1		10 Aug, 2020	Extinguished

Strength	Dosage	Availability
0.3%;0.1%	SUSPENSION/DROPS;OTIC	Prescription

CIPRODEX family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic